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Sirs: The 3243A>G point mutation
in mitochondrial DNA (mtDNA) is
associated with the MELAS
(mitochondrial encephalopathy
with lactic acidosis and stroke-like
episodes) syndrome, and some-
times with additional phenotypes
like a sensorimotor polyneuropa-
thy [4, 6]. The occurrence of a
small-ﬁber peripheral neuropathy
as the presenting clinical mani-
festation of a 3243A>G point
mutation in mtDNA has, accord-
ing to our knowledge, not been
described previously.
A 35 year old man was referred
to our neuromuscular clinic with a
history of a tingling sensation in
the toes of both feet, which has
been present for two to three
years, as well as a restless feeling
in the legs for many years. One
year before presentation he
developed burning pain in the toes
and then ﬁngers bilaterally. He
reported no weakness and had no
complaints suggestive of an auto-
nomic disturbance. There was no
history of alcohol or drug abuse.
He was otherwise healthy and used
no medication. Previously, his
mother was diagnosed with the
3243A>G point mutation in mito-
chondrial DNA at the age of 51
years after presenting with ptosis,
external ophthalmoplegia, limb-
girdle weakness and long-standing
diabetes mellitus. She had a
mtDNA mutation load of 0.8% in
leukocytes and 50% in skeletal
muscle.
On examination no muscle
atrophy or weakness was evident
and all tendon reﬂexes, including
the ankle jerks, were normal. All
sensory modalities were intact,
including vibration sense testing
with a Rydel-Seiffer tuning fork.
No ataxia was present and the gait
was undisturbed. Extensive inves-
tigations including vitamins B1,
B6, B12, folic acid, serum lactate,
creatine kinase, thyroid function
tests, fasting serum glucose and
HbA1c, serum lipid proﬁle,
angiotensin converting enzyme
levels and serum protein electro-
phoresis were normal. Anti-nu-
clear, anti-SS-A and SS-B, anti-
gliadin, anti-endomysial and an-
tineutrophil cytoplasmic (cyto-
plasmic and perinuclear)
antibodies as well as cryoglobulins
were all negative. Cranial magnetic
resonance imaging and electro-
cardiography were normal. Leu-
kocyte DNA examination revealed
the 3243A>G mtDNA point
mutation. The percentage of mu-
tated mtDNA in leukocytes was
16%.
Motor and sensory nerve con-
duction studies and F-responses
were performed in the upper and
lower limbs and were all normal,
as was the Hoffman reﬂex of the
soleus muscle. Concentric needle
EMG of distal muscles in the up-
per and lower limbs was normal.
Quantitative sensory threshold
testing (CASE IV) of the left foot
was performed according to the
manufacturer’s protocols. Cold
thermal threshold and heat pain
was evaluated and the results were
compared with normative data.
For both cold thermal threshold
and heat pain the values obtained
were above the 99
th percentile,
indicating hypoesthesia. In addi-
tion, cardiovagal autonomic tests
assessing sympathetic and para-
sympathetic responses were nor-
mal. After 18 months of follow-up,
no progression of symptoms or
involvement of large sensory or
motor ﬁbers is evident.
We suggest a direct causal
relationship between the docu-
mented mutation in mtDNA and
the small-ﬁber neuropathy in this
patient, as extensive investigations
did not reveal another explanation.
The exact prevalence of neur-
opathies in patients with MELAS
and the 3243A>G mutation in
mtDNA is unknown, but estimates
range from 5 to 97% [1, 4, 5].
Small-ﬁber involvement, isolated
or in combination with large-ﬁber
involvement, is probably under-
recognised. Most studies included
only patients with abnormalities
on nerve conduction studies,
thereby effectively excluding pa-
tients with isolated small-ﬁber
neuropathies. In patients present-
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thies, small-ﬁber involvement may
be overshadowed by large-ﬁber
involvement and thus go undiag-
nosed. Furthermore, these studies
provide no information regarding
the prevalence of neuropathies in
mutation carriers without the
MELAS syndrome.
Very little is known about the
possible mechanism of peripheral
nerve involvement in mitochon-
drial cytopathies. Mitochondrial
failure may just be one of a num-
ber of upstream events ultimately
leading to axonal degeneration via
the activation of calpain, a ﬁnal
pathway probably common to
many neuropathies [2]. Further-
more, in a study of vinblastine-
treated mice mitochondrial
dysfunction correlated strongly
with and preceded neurite
degeneration [3].
In conclusion, we describe a
patient with the MELAS 3243A>G
point mutation in mtDNA who
presented with clinical and elec-
trophysiological ﬁndings sugges-
tive of an isolated small-ﬁber
neuropathy. We postulate that
mitochondrial cytopathies should
be considered in the differential
diagnosis of small-ﬁber neuropa-
thies. Further studies are needed
to conﬁrm the relationship be-
tween mitochondrial disorders
and small-ﬁber neuropathies.
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